Spark Therapeutics, Inc. (NASDAQ:ONCE) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition
|
press release announcing unaudited consolidated financial results
for the quarter ended March 31, 2017. A copy of the press release
is being filed as Exhibit 99.1 to this Current Report on Form
8-K.
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by preference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
|
Item 9.01.
|
Financial Statements and Exhibits
|
furnished, and not filed:
|
Exhibit 99.1
|
Press release issued by Spark Therapeutics, Inc., dated
May 9, 2017. |
About Spark Therapeutics, Inc. (NASDAQ:ONCE)
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder. Spark Therapeutics, Inc. (NASDAQ:ONCE) Recent Trading Information
Spark Therapeutics, Inc. (NASDAQ:ONCE) closed its last trading session down -0.68 at 57.97 with 205,243 shares trading hands.